NDA 210238 · Akarx INC
Doptelet
Avatrombopag Maleate · Oral
NovelPriority reviewOrphanLast checked: Nov 20, 2026Latest source record: Jul 24, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
May 21, 2018
Approved uses
3
Original approval plus efficacy supplements
Registered trials
56
16 Phase 3, 5 recruiting
FAERS reports
2,368
839 serious, 138 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 13, 2025.
DOPTELET is a thrombopoietin receptor agonist indicated for the treatment of: Thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. ( 1.1 ) Thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. ( 1.2 ) Thrombocytopenia in pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia who have had an insufficient response to a previous treatment ( 1.3 ) 1.1 Treatment of Thrombocytopenia in Patients with Chronic Liver Disease (CLD) DOPTELET is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. 1.2 Treatment of Thrombocytopenia in Adult Patients with Chronic Immune Thrombocytopenia (ITP) DOPTELET is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. 1.3 Treatment of Thrombocytopenia in Pediatric Patients 1 Year and Older with Persistent or Chronic Immune Thrombocytopenia (ITP) DOPTELET is indicated for the treatment of thrombocytopenia in pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.
Mechanism: Avatrombopag is an orally bioavailable, small molecule TPO receptor agonist that stimulates proliferation and differentiation of megakaryocytes from bone marrow progenitor cells, resulting in an increased production of platelets. Avatrombopag does not compete with TPO for binding to the TPO receptor and has an additive effect with TPO on platelet production.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 24, 2025 Supplement 10 · Efficacy OrphanLetterLabel
- Jun 26, 2019 Supplement 1 · Efficacy OrphanLetterLabel
- May 21, 2018 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLabelLetterReview
1 products under this application
- DOPTELET · AVATROMBOPAG MALEATE EQ 20MG BASE · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Avatrombopag" as an intervention, any sponsor and status, largest first.
- Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective ProcedureStatus unknown
Chinese PLA General HospitalAcademic, hospital or other
NCT04915287 · 476 participants (planned) · Start Jun 6, 2021 · Primary completion Jun 30, 2023
Drug: Avatrombopag maleate; Platelet transfusion and 1 more · For: Thrombocytopenia; Drugs; Chronic Liver Disease
Sites: Beijing, China
- Avatrombopag Combined With All-trans Retinoic Acid in the Treatment of Primary Immune ThrombocytopeniaPivotal-lookingNot yet recruiting
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT07278908 · 248 participants (planned) · Start Dec 2025 · Primary completion Dec 2028
Drug: Avatrombopag+All trans retinoic acid; Avatrombopag · For: ITP - Immune Thrombocytopenia
- Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective ProcedurePivotal-lookingCompleted
Eisai Inc.Eisai
NCT01972529 · 231 participants · Start Feb 2014 · Primary completion Jan 26, 2017
Drug: avatrombopag (lower baseline platelet count); placebo (lower baseline platelet count) and 2 more · For: Thrombocytopenia Associated With Liver Disease
Sites: Lancaster, California; Long Beach, California; Los Angeles, California · 109 sites in all
- The Holistic StudyPivotal-lookingNot yet recruiting
Ostfold Hospital TrustAcademic, hospital or other
NCT07051915 · 220 participants (planned) · Start Sep 15, 2025 · Primary completion Jan 31, 2028
Drug: Avatrombopag; Rituximab (Arm B) · For: Thrombocytopenia Purpura
- Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective ProcedurePivotal-lookingCompleted
Eisai Inc.Eisai
NCT01976104 · 204 participants · Start Nov 2013 · Primary completion Jan 30, 2017
Drug: avatrombopag (lower baseline platelet count); placebo (lower baseline platelet count) and 2 more · For: Thrombocytopenia Associated With Liver Disease
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 120 sites in all
- TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Pivotal-lookingStatus unknown
Institute of Hematology & Blood Diseases Hospital, ChinaAcademic, hospital or other
NCT05718856 · 166 participants (planned) · Start Feb 23, 2023 · Primary completion May 14, 2025
Drug: TPO-RAs; TPO-RAs combining anti-CD 20 monoclonal antibody · For: Primary Immune Thrombocytopenia (ITP)
Sites: Tianjin, China
- A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)Pivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07421167 · 164 participants (planned) · Start Aug 4, 2026 · Primary completion Jan 18, 2029
Drug: ianalumab; thrombopoietin receptor agonist (TPO-RA) · For: Primary Immune Thrombocytopenia (ITP); Primary Evans Syndrome (ES)
Sites: Chandler, Arizona; Fayetteville, Arkansas; Torrance, California · 24 sites in all
- Avatrombopag in Patients With End-stage Liver Disease and ThrombocytopeniaPivotal-lookingStatus unknown
Tongji HospitalAcademic, hospital or other
NCT04906083 · 150 participants (planned) · Start Feb 1, 2021 · Primary completion Dec 31, 2022
Drug: Avatrombopag; Standard medical treatment · For: Liver Failure; Thrombocytopenia; Decompensated Cirrhosis
Sites: Wuhan, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- platelet count decreased420
- drug ineffective333
- headache252
- platelet count increased217
- fatigue189
- nausea123
- product dose omission issue118
- platelet count abnormal117
- off label use116
- death95
- diarrhoea89
- inappropriate schedule of product administration82
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2013 | 1 |
| 2015 | 1 |
| 2018 | 64 |
| 2019 | 106 |
| 2020 | 269 |
| 2021 | 265 |
| 2022 | 237 |
| 2023 | 282 |
| 2024 | 315 |
| 2025 | 375 |
| 2026 | 453 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Doptelet (Avatrombopag Maleate)
2024 spending
$160M
Beneficiaries
2,329
11,800 claims
Per beneficiary
$68,560
$406.38 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $18,925,776 |
| 2021 | $34,706,105 |
| 2022 | $60,589,108 |
| 2023 | $96,044,175 |
| 2024 | $159,677,266 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.
Jurczak W, Chojnowski K, Mayer J, et al. · Br J Haematol 2018 · Clinical Trial, Phase III, Comparative Study
- Role of thrombopoietin receptor agonists in chemotherapy-induced thrombocytopenia: A meta-analysis.
Gurumurthy G, Kisiel F, Gurumurthy S, et al. · J Oncol Pharm Pract 2025 · Meta-Analysis
- Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.
Terrault N, Chen YC, Izumi N, et al. · Gastroenterology 2018 · Clinical Trial, Phase III, Randomized Controlled Trial
- Avatrombopag for the treatment of children and adolescents with immune thrombocytopenia (AVA-PED-301): a multicentre, randomised, double-blind, placebo-controlled, phase 3b study.
Grace RF, Leblebisatan G, Aydinok Y, et al. · Lancet Haematol 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Avatrombopag for chemotherapy-induced thrombocytopenia in patients with non-haematological malignancies: an international, randomised, double-blind, placebo-controlled, phase 3 trial.
Al-Samkari H, Kolb-Sielecki J, Safina SZ, et al. · Lancet Haematol 2022 · Clinical Trial, Phase III, Randomized Controlled Trial
- A phase 3, randomized, double-blind, active-controlled trial evaluating efficacy and safety of avatrombopag versus eltrombopag in ITP.
Tarantino MD, Bussel JB, Lee EJ, et al. · Br J Haematol 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: Akarx INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.